BioAtla Registers 8.18M Shares for New $40M Yorkville Standby Equity Facility
BCAB sits 22% above its 52-week low of $1.07.
Summary
BioAtla registered up to 8.18M shares for resale under a new $40M standby equity purchase agreement with Yorkville, replacing its terminated $15M facility. No shares have been sold yet, but the variable-price structure could dilute existing holders by roughly 490% if fully drawn.
Key Events · Financing and Capital Events · BCAB
-
New $40M Yorkville Standby Facility
BioAtla signed a Standby Equity Purchase Agreement with YA II PN, Ltd. on October 15, 2026 giving it the right, but not the obligation, to sell up to $40,000,000 of common stock over 36 months. It replaces the November 2025 $15M SEPA, which was terminated the same day after only $0.4M had been drawn.
-
8.18M Shares Registered for Resale
The S-1 covers 8,000,000 Advance Shares plus 182,110 Commitment Shares underlying Commitment Fee Warrants. If all were issued, they would equal about 490.5% of the 1,668,261 shares outstanding as of October 16, 2026.
-
Variable-Price Drip at 97% of VWAP
Yorkville pays 97% of the lowest daily VWAP over the three trading days starting on each advance notice date, with a 4.99% ownership blocker and a 3% placement fee to Tungsten Partners. Lower prices mean more shares issued for the same proceeds.
-
Survival Capital Amid Going Concern
BioAtla had $1.5M of cash at June 30, 2026, a going-concern warning, a 70% workforce cut, and was delisted from Nasdaq to the OTCQB on August 31, 2026. Proceeds are earmarked for working capital and R&D while the board runs a strategic-alternatives process.
Analysis · BCAB · Life Sciences
BioAtla has replaced its old $15M Yorkville standby line with a larger $40M one and is registering up to 8,182,110 shares for resale — roughly 490.5% of the 1,668,261 shares outstanding as of October 16, 2026 if every share were issued. For a company that had just $1.5M of cash at June 30, 2026, carries a going-concern warning, and was delisted from Nasdaq to the OTCQB on August 31, 2026, that is an enormous overhang. The structure is a variable-price drip: BioAtla can sell Yorkville shares at 97% of the lowest VWAP over a three-day pricing period, so the lower the stock falls the more shares it takes to raise the same dollars. Nothing has been sold yet — this is permission to sell up to $40M over 36 months at the company's discretion, and the 8M registered shares may not be enough to access the full commitment if the price stays near $1.31. The practical read: this is survival capital for a company exploring strategic alternatives, but it comes at the cost of severe dilution and persistent selling pressure from Yorkville's resales.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCAB was trading at $1.31 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $1.07 to $3,575.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.